Hanmi Pharmaceutical Ltd
Seongnam-si, Seoul, South Korea · Biotechnology, Health Care, Pharmaceutical
Hanmi Pharmaceutical Co. Ltd. is a biopharmaceutical company engaged in the research, development, manufacture, and marketing of innovative medicines with a focus on metabolic disorders, oncology, and rare diseases. With several partnerships and a global presence, Hanmi aims to enhance healthcare through cutting-edge therapies. The company is noted for its investment in research and development an
Key facts
- Headquarters
- Seongnam-si, Seoul, South Korea
- Employees
- 480
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Website
- hanmipharm.com
- Company page
Recent activity at Hanmi Pharmaceutical Ltd
- : Hanmi Pharmaceutical completes Aptose acquisition
- : Hanmi Pharm Licenses Oral Drug Delivery Platform to Gilead for Encequidar Development.
- : Hanmi Pharmaceutical Launches Countmate, an Automated Vial Dispensing Solution for the Canadian and US Markets.
- : Hanmi Pharm. Co., Ltd. Announces Novel Obesity Drug HM17321 Designed to Augment Fat Loss While Increasing Lean Muscle Mass.
Leadership
- Chulhyun Park, Managing Director
Verified email and direct lines for Hanmi Pharmaceutical Ltd’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Hanmi Pharmaceutical Ltd in the news
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy - PR Newswire (Aug 24, 2026)
- Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog) - PR Newswire (May 31, 2026)
- Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia - BioSpace (May 21, 2026)
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism - Fierce Biotech (Aug 24, 2026)
- Hanmi Pharm signs deal with Silanes to supply diabetes combo drug to Mexico - Korea Biomedical Review (Sep 15, 2025)
- Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate - Yonhap News Agency (Aug 24, 2026)
- BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease - PR Newswire (Oct 29, 2026)
Companies similar to Hanmi Pharmaceutical Ltd
- Esperion Therapeutics · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- Santhera Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- Kyowa Kirin International · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- Lupin · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
- INNOCAN PHARMA Corp · Biotechnology, Health Care, Pharmaceutical, pharmaceuticals
About Hanmi Pharmaceutical Ltd: questions and answers
What does Hanmi Pharmaceutical Ltd do?
Hanmi Pharmaceutical Co. Ltd. is a biopharmaceutical company engaged in the research, development, manufacture, and marketing of innovative medicines with a focus on metabolic disorders, oncology, and rare diseases. With several partnerships and a global presence, Hanmi aims to enhance healthcare through cutting-edge therapies. The company is noted for its investment in research and development an
Where is Hanmi Pharmaceutical Ltd headquartered?
Hanmi Pharmaceutical Ltd is headquartered in Seongnam-si, Seoul, South Korea.
How many employees does Hanmi Pharmaceutical Ltd have?
Hanmi Pharmaceutical Ltd has about 480 employees.
What is the latest news on Hanmi Pharmaceutical Ltd?
On Jul 01, 2026, Hanmi Pharmaceutical completes Aptose acquisition
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy